Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2010

Jan 13, 2010

291_ip_2010-01-13_3fb32cc4-b293-4f62-96a4-b404c5e77b86.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Deutsches Eig p enka italforum

Frankfurt – November 10, 2009

Safe Harbour

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic comp ,g y , g g etitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

C
o
m
p
a
n
y		 A
i
d
d
i
b
d
t
t
"
n
n
e
p
e
n
e
n
a
n
o
y
c
o
m
p
a
n
y
F
k
f
S
k
E
h
T
D
A
X
t
t
"
r
a
n
r
o
c
c
a
n
g
e
e
c
u
x
–
f
S
4
0
0
l
t
i
t
i
D
U
K
U
"
e
m
p
o
y
e
e
s
a
o
u
r
s
e
s
n
,
,
P
i
l
i
p
e
n
e		 O
6
0
C
t
i
b
d
b
d
H
A
L
"
v
e
r
a
n
o
y
p
r
o
g
r
a
m
s
a
s
e
o
n
u
S
t
l
l
i
i
t
h
h
i
"
r
o
n
g
a
a
n
c
e
s
w
p
a
r
m
a
c
o
m
p
a
n
e
s
M
i
l
d
l
i
l
l
t
t
"
e
s
o
n
e
s
a
n
r
o
a
e
s
o
n
a
p
r
o
g
r
a
m
s
y
T
T
h
h
l
l
e
c
n
o
o
g
y		 L
d
i
i
H
C
A
L
l
f
t
t
"
e
a
n
g
g
p
p
r
o
p
p
r
e
a
r
p
p
a
o
r
m
y
y
u
,
,
S
&
d
i
d
t
t
t
t
t
t
"
r
o
n
g
n
s
p
e
p
a
e
n
e
s
a
e
u
u
i
i
F
l
n
a
n
c
a
s		 f
f
€
0
0
P
i
t
b
l
i
t
t
d
4
"
r
o
a
e
c
o
m
m
e
r
e
v
e
n
u
e
s
o
o
v
e
r
m
,
C
f
€
h
b
l
1
4
0
"
a
s
a
a
n
c
e
o
a
p
p
r
o
x
m

HuCAL PLATINUM: Technology p Leadershi p

Modular gene design & construction

  • HuCAL (Human Combinatorial Antibody Library)
  • Antibodies are fully human are
  • Robust intellectual property
  • HuCAL PLATINUM launched in December 2008
  • Unique built Unique, built -in optimization capabilities in

Optimization of antibodies delivers superior drug candidates

Building g yp a Strong Antibody Pipeline

Current Product Pipeline: 68 Programs Ongoing

N
a
m
e		 P
t
a
r
n
e
r		 T
t
a
r
g
e		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
B
H
Q
8
8
0		 N
t
i
o
v
a
r
s		 D
K
K-
1		 C
a
n
c
e
r
d
d.
n
n.		 C
t
e
n
o
c
o
r		 d
d.
n
n.		 I
l
/
m
m
n
o
o
g
g
u
y
y
C
a
n
c
e
r
G
t
b
a
n
e
n
e
r
m
a
u		 R
h
o
c
e		 β
A
l
i
d-
m
o
y		 A
D
d.
n.		 C
t
e
n
o
c
o
r		 d.
n.		 f
I
l
t
i
n
a
m
m
a
o
n		 6
2
P
t
a
r
n		 d
e
r
e
d.
n.		 N
i
t
o
v
a
r
s		 d.
n.		 d.
n.		 P
r
o
g
r
a
m		 s
d.
n.		 B
r S
a
e
y
h
i
c
e
r
n
g		 C
X (
A
I
M
N
)		 C
a
n
c
e
r
2
P
d
7
t
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 V
i
*
a
r
o
u
s
2
8
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
s
u		 V
i
a
r
o
s
u		 V
i
*
a
r
o
s
u
O
M
R
1
0
3		 - G
C
S
M
F
-		 R
A
M
O
R
2
0
2		 - C
D
3
8		 C
a
n
c
e
r
M
O
R
2
0
3		 - d.
n.		 C
a
n
c
e
r		 5
P
i
r
o
p
r		 t
e
a
r
y
M
O
R
2
0
5		 - d
d.
n.		 C
C
a
n
c
e
r		 P
r
o
g
g
r
a
m
s
O
M
R
1
0
4		 - d.
n.		 f
I
l
t
i
n
a
m
m
a
o
n
d.
n.		 M
h
S
/
o
r
p
o
y
s
N
t
i
o
v
a
r
s		 d.
n.		 d.
n.		 1
P
D
r
e-
e
v.		 P
r
o
g
r
a
m

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

Value Througg p h Strong Partnerships

2
0
0
7		 2
0
0
8		 2
0
0
9		 2
0
1
0		 2
0
1
1		 2
0
1
2
N
t
i
o
v
a
r
s
A
l
l
t
s
e
a
s
P
f
i
z
e
r
S
h
i
i
o
n
o
g
S
h
i
P
l
h
c
e
r
n
g
o
g
u
-
S
D
i
i
h
i
k
a
c
a
n
y
o
M
k
&
C
e
r
c
o
B
h
i
I
l
h
i
o
e
r
n
g
e
r
n
g
e
e
m
O
O
d
d
n
c
o
m
e		 C
i
d
t
t
t
o
m
m
e
e
r
m
E
l
i
L
i
l
l
y		 O
t
i
l
p
o
n
a
R
h
o
c
e		 E
i
t
x
e
n
s
o
n
s
B
S
S
h
h
i
i
a
e
r
c
e
r
n
g
y		 O
O
i
i
n
g
o		 i
i
b
b
d
d
t
t
n
g
a
n
o
p
y		 r
o
g
r
a
m
s
C
t
e
n
o
c
o
r
P
h
r
o
c
o
n

¾62 active partnered therapeutic antibody programs

¾ Potential for >100 programs still to be started >100

A New Alliance in Infectious Diseases

  • New alliance signed in October 2009
  • First collaboration for HuCAL PLATINUM -based drug discovery based in infectious diseases
  • Discovery and development of therapeutic antibodies for hospital -acquired ( acquired (nosocomial nosocomial) infections )
  • Daiichi Sankyo commits to funding the development of certain infectious disease specific technology at MorphoSys
  • Committed license fees and R&D funding in addition to success-based development milestones

Partnership yp p g s: Typical Terms per Program

Partnered HuCAL Antibodies in ClinicBHQ880 (Novartis)

The Drug

  • HuCAL I g y G1 antibod
  • Targeting DKK-1
  • − Overexpression of DKK-1 by myeloma cells may upset the normal balance b t e ween ost bl t eo as s an d ost lt eocasts
  • DKK-1 may play a role in preventing osteolytic bone disease in multiple myeloma patients

Development

  • Phase 1/2 study is ongoing in the US
  • Preclinical studies support the hypothesis that BHQ880 promotes bone formation and thereby inhibits tumor-inducedosteolytic disease
  • A phase 1/2 combination study in combination with Zometa/Reclast in relapsed or refractory myeloma patients has started in February 2009

Partnered HuCAL Antibodies in Clinic(Centocor)

The Drug

HuCAL I g y G1 antibod

Development

  • Ongoing phase 2 study in oncology started in October 2009 Ongoing study oncology,
  • Ongoing phase 2 in IPF (Idiopathic Pulmonary Fibrosis), started in October 2008

Partnered HuCAL Antibodies in ClinicGantenerumab (Roche)

The Drug

  • HuCAL IgG1 antibody
  • Targeting amyloidβ
  • Depolymerizes aggregated A β
  • C bl d rosses bloo -bib i it i brain barrier in transgenic mouse, decreasing cerebral A β burden

Development

  • Two Phase 1 studies completed (single dose arm and multip g) le ascendin g dose arm)
  • Mild-to-moderate Alzheimer's patients
  • Randomized, double-blind
  • Antibody behaved as expected as

Roche plans to move into phase 2 during 2010

Additional Partnered HuCAL Antibodies in Clinical Trials

Partnered Business: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

MOR103, a fully human HuCAL antibody targeting GM-CSF

  • GM-CSF p y la s a central role in inflammation and auto-immunity
  • Data support development of GM-CSF mAb therapy in different inflammatory diseases (RA, multiple sclerosis) and lung diseases
  • MOR103 blocks binding of GM GM-CSF to its receptor with sub CSF sub-pM affinity
  • Production of clinical material with PER.C6® cell line (Crucell)

MOR103Clinical Development

  • Primary indication: Rheumatoid arthritis (RA)
  • Commercial opp y ortunity: Anti-TNF therapies such as Enbrel, Remicade, Humira are successful biologic products for treating RA, but fewer than 25% of RA patients are adequately treated
  • Successful completion of phase 1 in healthy volunteers completion healthy
  • European phase 1b/2a study to start in 2009
  • Enrollment of 135 patients with active RA despite previous therapy with NSAID ti t id DMARD d/ tiNSAIDs, corticosteroids, DMARDs and/or anti-TNF-al hp a
  • 4 infusions of either MOR103 or placebo in three ascending dose cohorts
  • The primary endpoint of the trial is to determine the safety and tolerability of multiple doses of up to 1.5 mg/kg of MOR103 in patients with active RA
  • Secondary outcome measures will evaluate pharmacokinetics, immunogenicity, and the drug's potential to improve clinical signs and symptoms of RA
  • Enrollment is expected to be completed in the first half of 2011. The final results of the trial are expected in H1 2012

MOR202Proprietary Cancer Program

  • MOR202, a fully human HuCAL antibody, targeting CD38, a 45 kDa ectoenzyme heavily over-exp p ressed in 95% of multiple myeloma and some leukemia cell lines
  • Function: Induces cell-killing by ADCC, CDC & apoptosis
  • Primary indication: Multiple myeloma indication:
  • Commercial opportunity
  • 10 % of hematological cancers / 1% of all cancers / 2% of cancer deaths
  • No curative therapies
  • Median survival 24 – 30 months, all patients eventually relapse

Outlook 2009:

  • Further evaluation in animal models of multiple myeloma
  • Start of non-clinical safety study to support clinical testing
  • St t f li i l ffi t di i d i di ti Start of preclinical efficacy studies in second indication
  • Production and release of mAb material for animal safety testing and in preparation for phase 1/2a clinical testing in 2010

  • Production of clinical material with PER.C6® cell line

  • Several co-development options within strategic partnership

  • S & f ( %) Shared costs & profits (sliding scale up to 50%)
  • Galapagos:
  • Novel antibodies in bone & joint disease
  • Combined technologies & expertise
  • Screening of co-development, in-licensing and acquisition opportunities ongoing

Propy p rietary Product Pipeline: Strategy & Growth

  • Focus on inflammation & cancer
  • Six proprietary programs currently ongoing
  • Programs/targets are selected to take advantage of unique capabilities of HuCAL technology to generate drug candidates with i tith superior prospects
  • Co-development opportunities:
  • Novartis:

Clinical Pipeline

Clinical Antibody Pipeline is a Key Value Driver

AbD Serotec: The Business

CUSTOM

  • Greater footprint in diagnostic markets

  • Syner gies with Rx segment

  • Depends on public and private R&D budgets

  • Large customer base, tool Leverage own sales y g to establish brand

  • Fewer customers, larger orders

  • force

AbD Serotec: Emerg g pp in O ortunities in Diagnostics

T
h
l
f
h
h
l
l
i
i
b
l
i
h
t
t
t
e
g
o
a
o
e
r
e
s
e
a
r
c
a
a
n
c
e
s
o
e
s
a
s
a
i
f
h
h
b
b
l
l
H
H
C
C
A
A
L
L
b
b
d
d
i
i
b
b
d
d
i
i
t-
t
t
t
t
t
s
e
r
e
s
o
e
e
a
a
s
s
a
a
e
e
a
a
s
s
e
e
a
a
n
n
o
o
e
e
s
s
a
s
u
u
-
k
f
l
d
i
i
h
t
t
t
t
t
t
e
c
o
m
p
o
n
e
n
s
o
n
o
e
a
g
n
o
s
c
e
s
s
a
a
r
e
y
v
b
i
i
l
l
i
t
t
t
r
o
s
n
r
o
p
c
a
c
m
a
e
s
u
P
h
d
i
h
i
l
d
i
i
f
H
H
C
C
A
A
L
L
t
a
a
a
s
m
p
e
m
e
n
e
a
s
s
e
e
r
r
e
e
s
s
o
u

b
d
b
i
i
b
d
i
i
i
k
d
t
t
t
t
a
s
e
r
e
c
o
m
n
a
n
a
n
o
e
s
n
s
m
a
r
e
e
i
V
l
i
™
d
E
l
i
A
™
t
t
t
a
u
o
m
m
u
n
e
e
s
s
a
r
e
s
a
a
n
S
f
l
t
t
t
i
b
d
i
h
i
h
u
p
p
y
a
g
r
e
e
m
e
n
o
r
w
o
a
n
o
e
s
w
c
S
f
i
i
l
l
i
i
i
l
i
i
l
t
t
p
n
r
e
a
c
w
n
c
o
r
p
o
r
a
e
n
a
s
e
r
e
s
o
c
n
c
a
d
i
t
i
k
i
t
a
g
n
o
s
c
s
C
P
t
i
k
h
d
d
l,
H
A
L
b
d
r
o
e
o
m
a
a
s
o
r
e
r
e
n
o
v
e
u
a
s
e
-
,
f
h
t
i
b
d
i
i
t
b
d
r
e
s
e
a
r
c
a
n
o
e
s
a
g
a
n
s
a
r
o
a
r
a
n
g
e
o
f
t
t
l
l
i
d
d
i
t
i
t
t
h
d
t
i
a
r
g
e
m
o
e
c
u
e
s
n
a
o
n
o
e
p
r
o
u
c
o
n
o
S
t
i
t
i
l
t
A
b
D
t
a
n
g
e
n
m
a
e
r
a
a
e
r
o
e
c

¾ AbD Serotec has ongoing collaborations with more than 20 diagnostic customers hasmore

MorphoSys AG – Company Update – November 2009 © MorphoSys AG MorphoSys Page 24

Growth

AbD Serotec 9-months 2009 revenues: months +10%

gress

Market growing at 3 – 5%

AbD Serotec: Solid Pro

Profit

  • AbD Serotec now solidl y profitable
  • Investing now for future growth
  • Profit mar g p in of u p to 6%
  • Diagnostics
  • First HuCAL antibody in a diagnostic kit (Phadia)
  • M lti l di ti j t i ultiple agnostic projects on g oing
  • Management
  • Dieter Feger, SVP – new head of unit
  • 20 years in sales & marketing at Abbott Diagnostics

MorphoSys Group Financial Guidance 2009

2009E*

G
O
i
P
f
i
t
t
r
o
u
p
p
e
r
a
n
g
r
o		 8
1
1
–		 1
6
4
f
&
►
I
I
l
l
i
i
R
D
i
i
E
U
R
1
8
2
0
t
t
t
t
t
t
t
t
t
t
t
t
n
c
r
e
a
s
e
o
o
a
p
r
o
p
r
e
a
r
y
n
v
e
s
m
e
n
o
–
(
)
i
l
l
i
2
0
0
8
E
U
R
7
7
i
l
l
i
m
o
n
:
m
o
n

Total Group Revenues 80 – 85 71.6

2008A

MorphoSys Group Outlook

In EUR millions

  • Aiming for 10%–20% annual revenue growth
  • M i t i fit bilit hil t th i i li aintain profit ability, while strengthening pipeline

Shareholder Structure and Key Financials

Shareholder Structure

Key Financials (9-Months 2009)

Future Value Creation

Thank You.

www.morphosys.com

Dave Lemus

Chief Financial Officer

Phone +49 (0)89 / 899 27-439 ( ) ( ) Fax +49 (0)89 / 899 27-5439 Email [email protected]

Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →